Revenue for the quarter increased 31.3% YoY to ₹161.2 Cr, up from ₹122.8 Cr in Q3 of the previous financial year. EBITDA grew at a faster pace of 42.4% YoY to ₹30.8 Cr, compared with ₹21.6 Cr a year ago, reflecting better cost control and operating leverage.
Operating margin expanded to 19.1% from 17.6% YoY, indicating improved profitability despite ongoing cost pressures across the sector. The strong margin performance highlights the company’s focus on operational efficiency and disciplined execution.
Also read: Bajaj Healthcare secures exclusive rights to manufacture, market Magnesium L Threonate in India
Overall, Bajaj Healthcare’s Q3 performance underscores steady growth across key financial metrics, driven by higher revenues and margin expansion, positioning the company well for the remainder of the financial year.
Bajaj Healthcare shares closed at ₹389.30 on the NSE, down ₹4.85, or 1.23%, on 16 January 2026.
/images/ppid_59c68470-image-176857262091470484.webp)


/images/ppid_59c68470-image-176848503737660487.webp)
/images/ppid_59c68470-image-176856011051968246.webp)
/images/ppid_59c68470-image-17683975591796805.webp)
/images/ppid_59c68470-image-176856004067916288.webp)
/images/ppid_59c68470-image-176857003630644200.webp)
/images/ppid_59c68470-image-17685450389293444.webp)
/images/ppid_59c68470-image-176829752857179440.webp)
/images/ppid_59c68470-image-176836502950526525.webp)
/images/ppid_59c68470-image-176829266020611994.webp)